<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03049280</url>
  </required_header>
  <id_info>
    <org_study_id>ISI dV SP-TORS - 01</org_study_id>
    <nct_id>NCT03049280</nct_id>
  </id_info>
  <brief_title>Prospective, Multicenter da Vinci® SP™ Surgical System TORS Study</brief_title>
  <official_title>A Prospective, Multicenter Investigation of the da Vinci® SP™ Surgical System in TORS Procedures for Resection of Malignant Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intuitive Surgical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intuitive Surgical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, multicenter investigation of the da Vinci® SP™ Surgical System in Transoral
      Robotic Surgery (TORS) procedures for malignant oropharyngeal tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, multicenter investigation to evaluate the safety and clinical performance of
      the da Vinci SP Surgical System, instruments, and accessories in TORS procedures for
      malignant oropharyngeal tumors classified as T1 and T2.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 17, 2017</start_date>
  <completion_date type="Actual">December 26, 2017</completion_date>
  <primary_completion_date type="Actual">November 14, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Performance</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Performance defined as the conversion to an open approach required to complete the procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with device-related serious adverse events</measure>
    <time_frame>Intraoperative through 7 weeks post-operative</time_frame>
    <description>Safety is determined by measuring the number of subjects that experience device-related serious adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive surgical margin</measure>
    <time_frame>Through14-days postoperatively</time_frame>
    <description>Rate of final positive surgical margins confirmed by pathology</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Oropharyngeal Cancer</condition>
  <arm_group>
    <arm_group_label>Transoral robotic surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transoral robotic surgery</intervention_name>
    <description>Transoral robotic surgery for T1 &amp; T2 oropharyngeal cancers</description>
    <arm_group_label>Transoral robotic surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

          -  T1 or T2 malignant oropharyngeal tumor

          -  Tumor amenable to transoral resection

          -  No previous treatment for the index tumor

          -  Willing and able to provide written informed consent

          -  Willing and able to comply with the study protocol requirements

        Exclusion Criteria:

          -  T3 or T4 stage tumor

          -  Previous radiation treatment to the head and neck, with or without chemotherapy

          -  Evidence of other primary cancers or distant metastasis or subject with synchronous
             primary tumor excluding skin cancers

          -  Pre-operative expectation of needing microvascular soft-tissue reconstruction

          -  Tumor that invades and/or abuts the internal and/or external carotid artery

          -  Retropharyngeal carotid artery coincident with a tonsillar cancer or posterior
             pharyngeal wall cancer

          -  Evidence of mandibular invasion of tumor

          -  Eastern Cooperative Oncology Group Performance Status score greater than or equal to 2

          -  On a medication that interferes with clotting that cannot be stopped prior to surgery

          -  Contraindication for general anesthesia or surgery

          -  Mentally handicapped or has psychological disorder or severe systemic illness that
             would preclude compliance with study requirements or ability to provide informed
             consent

          -  Pregnant or suspected to be pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Holsinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Board of Trustees of the Leland Stanford Junior University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Celebration</city>
        <state>Florida</state>
        <zip>34747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trustees of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>January 30, 2017</study_first_submitted>
  <study_first_submitted_qc>February 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2017</study_first_posted>
  <last_update_submitted>August 7, 2018</last_update_submitted>
  <last_update_submitted_qc>August 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

